Tofogliflozin

The article presents a detailed analysis of various studies on the effects of different medications, primarily focusing on fracture risk and other health outcomes. It includes data on the types of medications, their doses, study durations, and the statistical results of their effects on conditions like diabetes, kidney disease, and heart failure. The studies use different methodologies, such as fixed and random effects models, and cover a wide range of drugs including SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, and others. The results indicate varying levels of effectiveness and safety across different medications and doses, with some showing significant impacts on reducing fracture risk and others demonstrating less conclusive results. The article emphasizes the importance of considering these findings in the context of patient care and treatment decisions.

Study assesses cost-utility of adding SGLT2i to SoC for T2D-HF patients in Thailand, finding canagliflozin, dapagliflozin, empagliflozin, or SGLT2i in general not cost-effective; however, price reductions would make them so. The study uses NHSO data, interviews, and SRNMA for model inputs, highlighting the need for local cost-utility analyses in LMICs.